Proteasome inhibitors in cancer therapy: lessons from the first decade

RZ Orlowski, DJ Kuhn - Clinical cancer research, 2008 - AACR
The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its
function is crucial to cellular homeostasis. First synthesized as probes of proteolytic …

Nuclear factor-κB in development, prevention, and therapy of cancer

C Van Waes - Clinical cancer research, 2007 - AACR
Nuclear factor-κB (NF-κB) is a signal transcription factor that has emerged as an important
modulator of altered gene programs and malignant phenotype in development of cancer …

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway

YG Lin, AB Kunnumakkara, A Nair, WM Merritt… - Clinical Cancer …, 2007 - AACR
Purpose: Curcumin, a component of turmeric, has been shown to suppress inflammation
and angiogenesis largely by inhibiting the transcription factor nuclear factor-κB (NF-κB). This …

Proteasome function is required for DNA damage response and fanconi anemia pathway activation

C Jacquemont, T Taniguchi - Cancer research, 2007 - AACR
Proteasome inhibitors sensitize tumor cells to DNA-damaging agents, including ionizing
radiation (IR), and DNA cross-linking agents (melphalan and cisplatin) through unknown …

[HTML][HTML] Tumor–host cell interactions in ovarian cancer: pathways to therapy failure

EP von Strandmann, S Reinartz, U Wager, R Müller - Trends in cancer, 2017 - cell.com
Although most ovarian cancer patients are highly responsive to chemotherapy, they
frequently present with recurrent metastatic lesions that result in poor overall survival, a …

Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer

CM Annunziata, HT Stavnes, L Kleinberg, A Berner… - Cancer, 2010 - Wiley Online Library
BACKGROUND: Recent work has suggested a role for nuclear factor κB (NF‐κB) in the
propagation of ovarian cancer cell lines, but the significance and mechanism of NF‐κB in …

Molecular pathways: the balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-κB signaling for cancer …

KP Zeligs, MK Neuman, CM Annunziata - Clinical Cancer Research, 2016 - AACR
The NF-κB signaling pathway is a complex network linking extracellular stimuli to cell
survival and proliferation. Cytoplasmic signaling to activate NF-κB can occur as part of the …

HOX genes and the NF-κB pathway: a convergence of developmental biology, inflammation and cancer biology

P Pai, S Sukumar - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2020 - Elsevier
The roles of HOX transcription factors as oncogenes and tumor suppressor genes, and the
NF-KB pathway in chronic inflammation, both leading to cancer are well-established. HOX …

The proteasome as a potential target for novel anticancer drugs and chemosensitizers

KR Landis-Piwowar, V Milacic, D Chen, H Yang… - Drug resistance …, 2006 - Elsevier
A major challenge in cancer therapy is tumor drug resistance. To overcome it, it is essential
to understand the mechanisms and identify the molecules involved, so that they can be …

Nuclear factor-kappa B: from clone to clinic

KS Ahn, G Sethi, BB Aggarwal - Current molecular medicine, 2007 - ingentaconnect.com
Nuclear transcription factor κB (NF-κB) was first discovered in 1986 in the nucleus of the B
cell as an enhancer in the κ immunoglobulin chain. However, this factor has identified in the …